WM
ADVM

WS Management’s Adverum Biotechnologies ADVM Stock Holding History

WS Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,862
Closed -$409K – 64
2021
Q3 		$409K Sell
18,862
-11,882
-39% -$303K 0.04% 68
2021
Q2 		$1.08M Sell
30,744
-40,000
-57% -$2.15M 0.11% 66
2021
Q1 		$6.97M Sell
70,744
-15,056
-18% -$1.81M 0.72% 34
2020
Q4 		$9.3M Hold
85,800
– – 0.97% 24
2020
Q3 		$8.84M Buy
85,800
+15,500
+22% +$2.32M 0.95% 26
2020
Q2 		$14.7M Sell
70,300
-11,395
-14% -$2.02M 1.8% 13
2020
Q1 		$7.98M Buy
81,695
+28,700
+54% +$3.35M 0.87% 30
2019
Q4 		$6.11M Sell
52,995
-4,570
-8% -$403K 0.52% 34
2019
Q3 		$3.14M Sell
57,565
-3,855
-6% -$434K 0.24% 50
2019
Q2 		$7.3M Sell
61,420
-27,452
-31% -$2.27M 0.47% 42
2019
Q1 		$4.66M Sell
88,872
-39,668
-31% -$1.6M 0.28% 49
2018
Q4 		$4.05M Buy
128,540
+13,540
+12% +$551K 0.2% 54
2018
Q3 		$6.96M Buy
+115,000
New +$6.46M 0.23% 51

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

WS Management's ADVM Position: Q4 2021 in Review

WS Management sold out of Adverum Biotechnologies (ADVM) in Q4 2021, closing a stake of 18,862 shares — an estimated $409K sold.

WS Management first reported a position in ADVM in Q3 2018 and held it in 13 quarters. The position peaked at $14.7M in Q2 2020. 98 funds tracked by Wall St. Rank hold ADVM as of Q4 2021.

  • WS Management reported no remaining Adverum Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • WS Management sold 18,862 Adverum Biotechnologies shares in Q4 2021, an estimated $409K.
  • WS Management first reported a position in Adverum Biotechnologies in Q3 2018 and held it in 13 quarters.
  • WS Management's Adverum Biotechnologies position peaked at $14.7M in Q2 2020.
  • 98 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2021.

Based on WS Management's 13F filing for Q4 2021, filed 11 Feb 2022.